Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease.
In the present study, the potential role of 99mTc-PEG-liposome to determine the extent and severity of active disease of Crohn's colitis was investigated. Patients suspected of having an exacerbation of Crohn's disease underwent a 99mTc-PEG-liposome scan (740 MBq, imaging at 4 and 24 h p.i.). A barium enema or endoscopy was performed as the standard verification procedure. Disease activity indices (Clinical Disease Activity Index and Van Hees Activity Index) were calculated. In seven patients positive images of colon segments affected by Crohn's colitis were obtained using 99mTc-PEG-liposomes. Only a moderate relation between 99mTc-liposome scan grading and verification procedures was found (Spearman rank r = 0.22). In accordance with previous studies, no significant correlation was found between the clinical disease activity indices and the verification procedures. This study was prematurely terminated because of unacceptable side-effects in 3 out of 9 patients, which occured almost immediately after starting the infusion. The complaints consisted of dyspnea and facial erythema. The symptoms were self-limiting when the infusion was stopped. In conclusion, the extent of Crohn's colitis can be established non-invasively with 99mTc-PEG-liposome scintigraphy. However, in view of the encountered side-effects, the PEG-liposomal preparation may have to be modified.
Brouwers
A H
AH
Department of Nuclear Medicine, University Medical Center Nijmegen, The Netherlands. a.brouwers@nugen.azn.nl
De Jong
D J
DJ
Dams
E T
ET
Oyen
W J
WJ
Boerman
O C
OC
Laverman
P
P
Naber
T H
TH
Storm
G
G
Corstens
F H
FH
D000328:Adult; D001466:Barium Sulfate; D003092:Colitis / Q000000981:diagnostic imaging; D003113:Colonoscopy; D003424:Crohn Disease / Q000000981:diagnostic imaging*; D004733:Enema; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D015203:Reproducibility of Results; D013667:Technetium / Q000008:administration & dosage / Q000009:adverse effects
D008081:Liposomes; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D001466:Barium Sulfate; D011092:Polyethylene Glycols; D013667:Technetium